Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total value of $76,923.84. Following the sale, the director now directly owns 7,077,560 shares of the company's stock, valued at approximately $47,561,203.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.67, for a total value of $76,351.49.
- On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34.
- On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.84, for a total transaction of $78,297.48.
- On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69.
- On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.12, for a total value of $81,502.64.
- On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.82, for a total transaction of $78,068.54.
Recursion Pharmaceuticals Stock Performance
The latest trend in real estate
From Pacaso | Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way.
Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.
Shares of RXRX stock opened at $6.32 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of -3.90 and a beta of 0.80. The company has a fifty day moving average price of $6.66 and a two-hundred day moving average price of $7.65. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same quarter in the previous year, the business posted ($0.38) EPS. The company's revenue for the quarter was up 30.9% on a year-over-year basis. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in RXRX. Perceptive Advisors LLC bought a new position in Recursion Pharmaceuticals during the second quarter worth $5,769,000. Capstone Investment Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $161,000. Benjamin F. Edwards & Company Inc. grew its stake in Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company's stock valued at $1,274,000 after buying an additional 167,302 shares during the last quarter. Scientech Research LLC bought a new position in Recursion Pharmaceuticals in the 2nd quarter valued at about $1,052,000. Finally, Ghisallo Capital Management LLC acquired a new stake in Recursion Pharmaceuticals during the second quarter worth approximately $8,250,000. Institutional investors own 89.06% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on RXRX shares. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. KeyCorp reduced their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Finally, Needham & Company LLC lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $9.40.
Read Our Latest Analysis on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
